Literature DB >> 25231693

Circulating progranulin level is associated with visceral fat and elevated liver enzymes: significance of serum progranulin as a useful marker for liver dysfunction.

Yuko Tanaka1, Tetsuya Takahashi, Yoshikazu Tamori.   

Abstract

Progranulin (PRGN) was recently identified as one of the adipokines involved in the development of insulin resistance. Thus, the aim of this study was to explore the importance of PRGN as a novel marker for metabolic diseases in Japanese. A total of 138 subjects were recruited by the Aijinkai Total Health Care Center. Physical examination, blood sample examination and total body CT scan were performed for all participants. Serum PRGN levels were examined in subjects with or without metabolic syndrome and with or without liver enzyme elevation. Association study of serum PRGN levels and regression analysis of the relationship of elevated liver enzymes to representative metabolic parameters were performed. The metabolic syndrome group exhibited older age, and higher BMI, blood pressure, fasting glucose, HbA1c, IRI, HOMA-R, TG, FFA, CRP, AST, ALT, LDH, and ALP, and larger visceral fat area, subcutaneous fat area and visceral fat area/subcutaneous fat area. Serum PRGN concentrations were significantly higher in the metabolic syndrome group than in the non-metabolic syndrome group. Bivariate correlation analysis revealed that serum PRGN concentrations correlated positively and significantly with AST, ALT, LDH, γGTP, ALP, waist circumference and visceral fat area. The group with elevated liver enzymes exhibited higher BMI, blood pressure, IRI, HOMA-R, and PRGN level and larger waist circumference and visceral fat area than the group without them. In logistic regression analysis, visceral fat area and PRGN were significantly predictive of elevated liver enzymes. These results suggest that serum PRGN level as well as visceral fat are associated closely with liver dysfunction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25231693     DOI: 10.1507/endocrj.EJ14-0210

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology.

Authors:  Xiaolai Zhou; Thomas Kukar; Rosa Rademakers
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The role of progranulin in diabetes and kidney disease.

Authors:  Bruna Bellincanta Nicoletto; Luis Henrique Canani
Journal:  Diabetol Metab Syndr       Date:  2015-12-21       Impact factor: 3.320

3.  Progranulin serum levels in human kidney transplant recipients: A longitudinal study.

Authors:  Bruna Bellincanta Nicoletto; Elis Forcellini Pedrollo; Larissa Salomoni Carpes; Natália Gomes Coloretti; Thaiana Cirino Krolikowski; Gabriela Corrêa Souza; Luiz Felipe Santos Gonçalves; Roberto Ceratti Manfro; Luis Henrique Canani
Journal:  PLoS One       Date:  2018-03-02       Impact factor: 3.240

Review 4.  Progranulin and Its Related MicroRNAs after Status Epilepticus: Possible Mechanisms of Neuroprotection.

Authors:  Peter Körtvelyessy; Tessa Huchtemann; Hans-Jochen Heinze; Daniel M Bittner
Journal:  Int J Mol Sci       Date:  2017-02-24       Impact factor: 5.923

5.  Progranulin attenuates liver fibrosis by downregulating the inflammatory response.

Authors:  Wonbeak Yoo; Jaemin Lee; Kyung Hee Noh; Sangmin Lee; Dana Jung; Mohammad Humayun Kabir; Dongmin Park; Cheolju Lee; Ki-Sun Kwon; Ji-Su Kim; Seokho Kim
Journal:  Cell Death Dis       Date:  2019-10-07       Impact factor: 8.469

6.  Increased Fat Taste Preference in Progranulin-Deficient Mice.

Authors:  Lana Schumann; Annett Wilken-Schmitz; Sandra Trautmann; Alexandra Vogel; Yannick Schreiber; Lisa Hahnefeld; Robert Gurke; Gerd Geisslinger; Irmgard Tegeder
Journal:  Nutrients       Date:  2021-11-17       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.